PBPIA
IMNM icon

Pivotal bioVenture Partners Investment Advisor’s Immunome IMNM Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Hold
732,512
– – 5.73% 6
2025
Q4 		$15.7M Buy
732,512
+230,000
+46% +$4.04M 6.08% 7
2025
Q3 		$5.88M Buy
+502,512
New +$5M 3.4% 6

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's IMNM Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor held its Immunome (IMNM) position steady in Q1 2026 at 732,512 shares worth $16M. The position accounts for 5.73% of the portfolio, ranked #6.

Pivotal bioVenture Partners Investment Advisor first reported a position in IMNM in Q3 2025 and has held it in 3 quarters since. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Pivotal bioVenture Partners Investment Advisor held 732,512 shares of Immunome worth $16M as of Q1 2026.
  • Pivotal bioVenture Partners Investment Advisor left its Immunome share count unchanged in Q1 2026.
  • Immunome made up 5.73% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #6 holding.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Immunome in Q3 2025 and has held it in 3 quarters since.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.